370 related articles for article (PubMed ID: 35326605)
41. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α-particles or Auger electrons.
Aghevlian S; Boyle AJ; Reilly RM
Adv Drug Deliv Rev; 2017 Jan; 109():102-118. PubMed ID: 26705852
[TBL] [Abstract][Full Text] [Related]
42. Radiometals as payloads for radioimmunotherapy for lymphoma.
DeNardo GL; Kennel SJ; Siegel JA; Denardo SJ
Clin Lymphoma; 2004 Oct; 5 Suppl 1():S5-10. PubMed ID: 15498149
[TBL] [Abstract][Full Text] [Related]
43. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.
Ma D; McDevitt MR; Barendswaard E; Lai L; Curcio MJ; Pellegrini V; Brechbiel MW; Scheinberg DA
Leukemia; 2002 Jan; 16(1):60-6. PubMed ID: 11840264
[TBL] [Abstract][Full Text] [Related]
44. Radioimmunotherapy of non-Hodgkin's lymphoma: molecular targeting and novel agents.
Pauwels EK; Erba P
Drug News Perspect; 2007 Mar; 20(2):87-93. PubMed ID: 17440631
[TBL] [Abstract][Full Text] [Related]
45. Clinical radioimmunotherapy.
Knox SJ; Meredith RF
Semin Radiat Oncol; 2000 Apr; 10(2):73-93. PubMed ID: 10727597
[TBL] [Abstract][Full Text] [Related]
46. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
47. Cure of incurable lymphoma.
DeNardo GL; Sysko VV; DeNardo SJ
Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S46-56. PubMed ID: 16979440
[TBL] [Abstract][Full Text] [Related]
48. ABCs of radioisotopes used for radioimmunotherapy: alpha- and beta-emitters.
Waldmann T
Leuk Lymphoma; 2003; 44 Suppl 3():S107-13. PubMed ID: 15202533
[TBL] [Abstract][Full Text] [Related]
49. Emerging trends for radioimmunotherapy in solid tumors.
Jain M; Gupta S; Kaur S; Ponnusamy MP; Batra SK
Cancer Biother Radiopharm; 2013 Nov; 28(9):639-50. PubMed ID: 23844555
[TBL] [Abstract][Full Text] [Related]
50. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
51. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
[TBL] [Abstract][Full Text] [Related]
52. General overview of radioimmunotherapy of solid tumors.
Navarro-Teulon I; Lozza C; Pèlegrin A; Vivès E; Pouget JP
Immunotherapy; 2013 May; 5(5):467-87. PubMed ID: 23638743
[TBL] [Abstract][Full Text] [Related]
53. Combination Radioimmunotherapy Strategies for Solid Tumors.
Zaheer J; Kim H; Lee YJ; Kim JS; Lim SM
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717302
[TBL] [Abstract][Full Text] [Related]
54. Cancer therapy with radiolabeled and drug/toxin-conjugated antibodies.
Govindan SV; Griffiths GL; Hansen HJ; Horak ID; Goldenberg DM
Technol Cancer Res Treat; 2005 Aug; 4(4):375-91. PubMed ID: 16029057
[TBL] [Abstract][Full Text] [Related]
55. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model: evaluation of toxicity, therapeutic effect, and tumor model.
Mårtensson L; Nilsson R; Ohlsson T; Sjögren HO; Strand SE; Tennvall J
Cancer; 2010 Feb; 116(4 Suppl):1043-52. PubMed ID: 20127949
[TBL] [Abstract][Full Text] [Related]
56. The new golden era for radioimmunotherapy: not just for lymphomas anymore.
Tomblyn MB; Katin MJ; Wallner PE
Cancer Control; 2013 Jan; 20(1):60-71. PubMed ID: 23302908
[TBL] [Abstract][Full Text] [Related]
57. Radioimmunotherapy of solid cancers: A review.
Kairemo KJ
Acta Oncol; 1996; 35(3):343-55. PubMed ID: 8679266
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal antibody based radiopharmaceuticals for imaging and therapy.
Lin M; Paolillo V; Le DB; Macapinlac H; Ravizzini GC
Curr Probl Cancer; 2021 Oct; 45(5):100796. PubMed ID: 34657748
[TBL] [Abstract][Full Text] [Related]
59. Radioimmunotherapy in non-Hodgkin lymphoma: Prediction and assessment of response.
Eskian M; Khorasanizadeh M; Kraeber-Bodere F; Rezaei N
Crit Rev Oncol Hematol; 2016 Nov; 107():182-189. PubMed ID: 27823646
[TBL] [Abstract][Full Text] [Related]
60. Radioimmunotherapy of experimental human metastatic melanoma with melanin-binding antibodies and in combination with dacarbazine.
Revskaya E; Jongco AM; Sellers RS; Howell RC; Koba W; Guimaraes AJ; Nosanchuk JD; Casadevall A; Dadachova E
Clin Cancer Res; 2009 Apr; 15(7):2373-9. PubMed ID: 19293257
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
